Table 3.

Human studies regarding the effect of medicinal plants in chemotherapy-induced neuropathy

Treatment	Design	Dosage	Duration	Results	Reference
α-lipoic acid	Randomized, double-blind, placebo-controlled trial in 70 subjects with chemotherapy-induced peripheral neuropathy	600 mg	24 w	No significant difference in any of the clinical outcomes	[43]
α-lipoic acid+ Boswellia serrata + MSM + bromelain	Prospective study in 25 subjects with chemotherapy-induced peripheral neuropathy	α-lipoic acid (240 mg) + B. serrata (40 mg) + MSM (200 mg) + bromelain (20 mg)	12 w	↓Pain (VAS), sensor and motor neuropathic impairment (NCI-CTC score), TNSc, mISS	[44]
Goshajinkigan	Randomized controlled trial in 29 patients with ovarian or endometrial cancer underwent TC therapy and developed peripheral neuropathy	7.5 g	6 w	↓Frequency of abnormal CPT, No significant change in VAS, NCI-CTCAE neuropathy grade, FACT-Taxane & CPT ranges	[45]
Nabiximols (oromucosal spray)	Double-blind, placebo-controlled, crossover pilot trial in 16 patients with chemotherapy-induced neuropathic pain	Maximum 12 puff per day	24 w	↓Pain (NRS-PI)	[46]
Goshajinkigan	Retrospective study in 73 colorectal cancer patients with oxaliplatin-induced peripheral neuropathy	2.5 g, TDS	≥4 w	↓Deleterious effects in comparison to non-treated patients	[47]

VAS visual analogue scale, MSM Methylsulfonylmethane, TNSC Total Neuropathy Score clinical version, mISS group sensory sum score, NCI-CTCAE National Cancer Institute–Common Toxicity Criteria for Adverse Event, NRSPI numeric rating scale for pain intensity, CPT current perception threshold, FACT-Taxane functional assessment of cancer therapy-Taxane